123 related articles for article (PubMed ID: 9826461)
1. Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model.
Dorigo O; Shawler DL; Royston I; Sobol RE; Berek JS; Fakhrai H
Gynecol Oncol; 1998 Nov; 71(2):204-10. PubMed ID: 9826461
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotide specific for transforming growth factor-beta 1 inhibit both in vitro and in vivo growth of MBT-2 murine bladder cancer.
Tzai TS; Lin CI; Shiau AL; Wu CL
Anticancer Res; 1998; 18(3A):1585-9. PubMed ID: 9673374
[TBL] [Abstract][Full Text] [Related]
3. Expression of an antisense transforming growth factor-beta1 transgene reduces tumorigenicity of EMT6 mammary tumor cells.
Park JA; Wang E; Kurt RA; Schluter SF; Hersh EM; Akporiaye ET
Cancer Gene Ther; 1997; 4(1):42-50. PubMed ID: 9012450
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.
Ali SA; McLean CS; Boursnell ME; Martin G; Holmes CL; Reeder S; Entwisle C; Blakeley DM; Shields JG; Todryk S; Vile R; Robins RA; Rees RC
Cancer Res; 2000 Mar; 60(6):1663-70. PubMed ID: 10749137
[TBL] [Abstract][Full Text] [Related]
5. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity.
Lin CY; Chuang TF; Liao KW; Huang YJ; Pai CC; Chu RM
Cancer Lett; 2008 Dec; 272(2):285-95. PubMed ID: 18760876
[TBL] [Abstract][Full Text] [Related]
6. IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile.
Horton HM; Dorigo O; Hernandez P; Anderson D; Berek JS; Parker SE
J Immunol; 1999 Dec; 163(12):6378-85. PubMed ID: 10586027
[TBL] [Abstract][Full Text] [Related]
7. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
8. Immunization with TGF-beta antisense oligonucleotide-modified autologous tumor vaccine enhances the antitumor immunity of MBT-2 tumor-bearing mice through upregulation of MHC class I and Fas expressions.
Tzai TS; Shiau AL; Liu LL; Wu CL
Anticancer Res; 2000; 20(3A):1557-62. PubMed ID: 10928070
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer.
Larchian WA; Horiguchi Y; Nair SK; Fair WR; Heston WD; Gilboa E
Clin Cancer Res; 2000 Jul; 6(7):2913-20. PubMed ID: 10914741
[TBL] [Abstract][Full Text] [Related]
10. FGF-2, IL-1beta and TGF-beta regulate fibroblast expression of S100A8.
Rahimi F; Hsu K; Endoh Y; Geczy CL
FEBS J; 2005 Jun; 272(11):2811-27. PubMed ID: 15943814
[TBL] [Abstract][Full Text] [Related]
11. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
Suzuki E; Kapoor V; Cheung HK; Ling LE; DeLong PA; Kaiser LR; Albelda SM
Clin Cancer Res; 2004 Sep; 10(17):5907-18. PubMed ID: 15355924
[TBL] [Abstract][Full Text] [Related]
12. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines.
Kobie JJ; Wu RS; Kurt RA; Lou S; Adelman MK; Whitesell LJ; Ramanathapuram LV; Arteaga CL; Akporiaye ET
Cancer Res; 2003 Apr; 63(8):1860-4. PubMed ID: 12702574
[TBL] [Abstract][Full Text] [Related]
14. Glioma-specific cytotoxic T cells can be effectively induced by subcutaneous vaccination of irradiated wild-type tumor cells without artificial cytokine production.
Iwadate Y; Yamaura A; Sakiyama S; Sato Y; Tagawa M
Int J Oncol; 2003 Aug; 23(2):483-8. PubMed ID: 12851699
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of cytokine gene expression during the in vitro CTL induction against a murine nonimmunogenic tumor.
Murata S; Eguchi Y; Mekata E; Tani T; Kodama M
Anticancer Res; 2000; 20(1A):363-72. PubMed ID: 10769681
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of macrophage transforming growth factor-beta messenger RNA expression by IL-7.
Dubinett SM; Huang M; Dhanani S; Wang J; Beroiza T
J Immunol; 1993 Dec; 151(12):6670-80. PubMed ID: 8258684
[TBL] [Abstract][Full Text] [Related]
17. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
18. Clonal restriction of the expansion of antigen-specific CD8+ memory T cells by transforming growth factor-{beta}.
Cheng ML; Chen HW; Tsai JP; Lee YP; Shih YC; Chang CM; Ting CC
J Leukoc Biol; 2006 May; 79(5):1033-42. PubMed ID: 16478921
[TBL] [Abstract][Full Text] [Related]
19. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy.
Won J; Kim H; Park EJ; Hong Y; Kim SJ; Yun Y
Cancer Res; 1999 Mar; 59(6):1273-7. PubMed ID: 10096559
[TBL] [Abstract][Full Text] [Related]
20. Suppression of tumor metastasis by blockade of transforming growth factor beta signaling in bone marrow cells through a retroviral-mediated gene therapy in mice.
Shah AH; Tabayoyong WB; Kundu SD; Kim SJ; Van Parijs L; Liu VC; Kwon E; Greenberg NM; Lee C
Cancer Res; 2002 Dec; 62(24):7135-8. PubMed ID: 12499244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
